Abstracts tagged "etanercept and rheumatoid arthritis (RA)"

Abstract Number: 484 • 2012 ACR/ARHP Annual Meeting
Comparison of Rheumatoid Arthritis-Related Health Care Resource Use and Comorbidities Among Patients with Rheumatoid Arthritis Treated with Adalimumab Vs. Etanercept
Jipan Xie¹, Arijit Ganguli², Hongbo Yang¹, Kejal Parikh¹, Eric Q. Wu¹ and Mary Cifaldi³, ¹Analysis Group Inc., Boston, MA, ²AbbVie, North Chicago, IL, ³Abbott Laboratories, Abbott Park, IL
Background/Purpose: Adalimumab (ADA) and etanercept (ETN) are two commonly used tumor necrosis factor (TNF)-α antagonists for the treatment of rheumatoid arthritis (RA). The study is…
Abstract Number: L10 • 2012 ACR/ARHP Annual Meeting
In Rheumatoid Arthritis Patients with Stable Low Disease Activity On Methotrexate Plus Etanercept, Continuation of Etanercept 50 Mg Weekly or 25 Mg Weekly Are Both Clinically Superior to Discontinuation: Results From a Randomized, 3-Armed, Double-Blind Clinical Trial
R.F. van Vollenhoven¹, Mikkel Østergaard², Marjatta Leirisalo-Repo³, Till Uhlig⁴, Marita Jansson⁵, Åsa Klackenberg⁵, Katherine Hutchinson⁶ and Karin Franck-Larsson⁵, ¹Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ²Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ³Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Speciality Care Nordic Medical Affairs, Pfizer Nordic, Sollentuna, Sweden, ⁶Quanticate, Hitchin, United Kingdom
Background/Purpose: The efficacy of etanercept (ETN) in combination with methotrexate (MTX) in the treatment of rheumatoid arthritis (RA) is well established, and long-term trials1 and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].